SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline include galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

Bowhead Specialty Holdings Inc

Armlogi Holding Corp

Jiade Ltd

Raytech Holding Ltd

Four IPOs debuted in the US this week, led by a Singapore-based hot pot restaurant operator, though the largest scheduled deal didn't make it to market. The week's largest scheduled deal, online casino games publisher Games Global withdrew its $254 million offering hours before it was expected to price, citing market conditions. Just one listing is currently scheduled for the week ahead, although smaller issuers may join the calendar throughout the week.

U.S. IPO Weekly Recap: Hot Pot Chain Leads The Week's IPOs As The Pipeline Gets A Billion-Dollar Boost

Galleinphi Inc. has filed proposed terms for a $15 million IPO of its ordinary shares. The company acts as a wholesaler of consumer electronics products in China. Galleinphi is producing declining revenue, negative gross profit, and substantial operating losses.

News for SELLAS Life Sciences Group Stock (GALE)